AU762574B2 - Method of inhibiting osteoclast activity - Google Patents

Method of inhibiting osteoclast activity Download PDF

Info

Publication number
AU762574B2
AU762574B2 AU39888/99A AU3988899A AU762574B2 AU 762574 B2 AU762574 B2 AU 762574B2 AU 39888/99 A AU39888/99 A AU 39888/99A AU 3988899 A AU3988899 A AU 3988899A AU 762574 B2 AU762574 B2 AU 762574B2
Authority
AU
Australia
Prior art keywords
ser
pro
leu
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU39888/99A
Other languages
English (en)
Other versions
AU3988899A (en
Inventor
Dirk M. Anderson
Laurent J. Galibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU3988899A publication Critical patent/AU3988899A/en
Application granted granted Critical
Publication of AU762574B2 publication Critical patent/AU762574B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU39888/99A 1998-05-14 1999-05-13 Method of inhibiting osteoclast activity Expired AU762574B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8548798P 1998-05-14 1998-05-14
US60/085487 1998-05-14
US11083698P 1998-12-03 1998-12-03
US60/110836 1998-12-03
PCT/US1999/010588 WO1999058674A2 (en) 1998-05-14 1999-05-13 Method of inhibiting osteoclast activity

Publications (2)

Publication Number Publication Date
AU3988899A AU3988899A (en) 1999-11-29
AU762574B2 true AU762574B2 (en) 2003-06-26

Family

ID=26772773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39888/99A Expired AU762574B2 (en) 1998-05-14 1999-05-13 Method of inhibiting osteoclast activity

Country Status (12)

Country Link
US (2) US20050089522A1 (https=)
EP (2) EP1076699B1 (https=)
JP (1) JP2002514418A (https=)
AT (2) ATE412746T1 (https=)
AU (1) AU762574B2 (https=)
CA (1) CA2328140C (https=)
CY (1) CY1111912T1 (https=)
DE (1) DE69939822D1 (https=)
DK (1) DK2009025T3 (https=)
ES (1) ES2317694T3 (https=)
PT (1) PT2009025E (https=)
WO (1) WO1999058674A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
EP1803816A3 (en) * 1996-12-13 2007-09-26 Schering Corporation Mammalian cell surface antigens; related reagents
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
KR100496063B1 (ko) 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP0975754B2 (en) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
US20030017151A1 (en) * 2001-05-17 2003-01-23 Dougall William C. Therapeutic use of rank antagonists
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2463478A1 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
JP5191487B2 (ja) * 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ATE240394T1 (de) * 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
MX9709447A (es) * 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規dna及びそれを用いた蛋白質の製造方法
EP1803816A3 (en) 1996-12-13 2007-09-26 Schering Corporation Mammalian cell surface antigens; related reagents
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
KR100496063B1 (ko) * 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP0975754B2 (en) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラopgポリペプチド
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) 1998-03-20 1999-10-05 Suntory Ltd NF−κBの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
DE60034871T2 (de) 1999-09-03 2008-01-17 Amgen Inc., Thousand Oaks Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DK2105449T3 (da) 2000-02-23 2019-10-07 Amgen Inc Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDERSON DM ET AL, NATURE, 1997, 390:175-179 *
LACEY DL ET AL, CELL, 1998, 93:165-176 *
YASUDA H ET AL, PNAS, 1998, 95:3597-3602 *

Also Published As

Publication number Publication date
CY1111912T1 (el) 2015-11-04
WO1999058674A3 (en) 2000-02-10
DE69939822D1 (de) 2008-12-11
JP2002514418A (ja) 2002-05-21
US20050089522A1 (en) 2005-04-28
CA2328140C (en) 2012-03-13
ES2317694T3 (es) 2009-04-16
EP2009025A1 (en) 2008-12-31
ATE412746T1 (de) 2008-11-15
WO1999058674A2 (en) 1999-11-18
DK2009025T3 (da) 2011-11-14
ATE517916T1 (de) 2011-08-15
EP2009025B1 (en) 2011-07-27
EP1076699A2 (en) 2001-02-21
AU3988899A (en) 1999-11-29
US20090004196A1 (en) 2009-01-01
EP1076699B1 (en) 2008-10-29
CA2328140A1 (en) 1999-11-18
US7790684B2 (en) 2010-09-07
PT2009025E (pt) 2011-09-19

Similar Documents

Publication Publication Date Title
AU762574B2 (en) Method of inhibiting osteoclast activity
US8333963B2 (en) Method of inhibiting osteoclast activity
US5674492A (en) Method of preventing or treating disease characterized by neoplastic cells expressing CD40
Nagata Fas and Fas ligand: a death factor and its receptor
KR101004174B1 (ko) 세포소멸을 유도하는 시토킨
CA2222914C (en) Novel cd40l mutein
CA2292899A1 (en) Ntn-2 member of tnf ligand family
WO1998055620A1 (en) Ntn-2 member of tnf ligand family
US20070298460A1 (en) Novel receptor that causes cell death
US20130101585A1 (en) Method of inhibiting osteoclast activity
EP0689600A1 (en) Process to induce the death of tumor cells
CA2316545A1 (en) Novel nucleic acid and polypeptide with homology to the tnf-receptors
ES2368101T3 (es) Procedimiento para inhibición de la actividad de los osteoclastos.
AU748168B2 (en) Viral encoded semaphorin protein receptor DNA and polypeptides
AU741504B2 (en) Receptor activator of NF-kappa B, receptor is member of TNF receptor superfamily
MXPA97010399A (es) Citocina que induce apoptosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired